↓ Skip to main content

Phase I clinical trial of a novel autologous modified-DC vaccine in patients with resected NSCLC

Overview of attention for article published in BMC Cancer, December 2017
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
1 tweeter
facebook
1 Facebook page
reddit
1 Redditor

Citations

dimensions_citation
14 Dimensions

Readers on

mendeley
27 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Phase I clinical trial of a novel autologous modified-DC vaccine in patients with resected NSCLC
Published in
BMC Cancer, December 2017
DOI 10.1186/s12885-017-3859-3
Pubmed ID
Authors

Chunlei Ge, Ruilei Li, Haifeng Song, Tao Geng, Jinyan Yang, Qinghua Tan, Linfeng Song, Ying Wang, Yuanbo Xue, Zhen Li, Suwei Dong, Zhiwei Zhang, Na Zhang, Jiyin Guo, Lin Hua, Siyi Chen, Xin Song

Abstract

The primary aim of this study was to evaluate the safety of a novel dendritic cell (DC) vaccine pulsed with survivin and MUC1, silenced with suppressor of cytokine signaling 1 (SOCS1), and immune stimulated with flagellin for patients with stage I to IIIA non-small cell lung cancer (NSCLC) in a phase I open-label, uncontrolled, and dose-escalation trial. Moreover, we evaluate the potential efficacy of this modified DC vaccine as secondary aim. The patients were treated with the vaccine at 1 × 106, 1 × 107and the maximum dose 8 × 107 at day 7, 14, and 21 after characterization of the vaccine phenotype by flow cytometry. The safety of the vaccine was assessed by adverse events, and the efficacy by the levels of several specific tumor markers and the patient quality of life. The vaccine was well tolerated without dose-limiting toxicity even at higher doses. The most common adverse event reported was just grade 1 flu-like symptoms without unanticipated or serious adverse event. A significant decrease in CD3 + CD4 + CD25 + Foxp3+ T regulatory (Treg) cell number and increase in TNF-α and IL-6 were observed in two patients. Two patients showed 15% and 64% decrease in carcino-embryonic antigen and CYFRA21, respectively. The vaccination with the maximum dose significantly improved the patients'quality of life when administered at the highest dose. More importantly, in the long-term follow-up until February 17, 2017, 1 patient had no recurrence, 1 patients had a progressive disease (PD), and 1 patient was died in the low dose group. In the middle dose group, all 3 patients had no recurrence. In the high dose group, 1 patient was died, 1 patient had a PD, and the other 7 patients had no recurrence. We provide preliminary data on the safety and efficacy profile of a novel vaccine against non-small cell lung cancer, which was reasonably well tolerated, induced modest antitumor activity without dose-limiting toxicity, and improved patients' quality of life. Further more, the vaccine maybe a very efficacious treatment for patients with resected NSCLC to prevent recurrence. Our findings on the safety and efficacy of the vaccine in this phase I trial warrant future phase II/III clinical trial.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 27 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 27 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 5 19%
Student > Bachelor 5 19%
Student > Ph. D. Student 5 19%
Other 3 11%
Student > Doctoral Student 2 7%
Other 4 15%
Unknown 3 11%
Readers by discipline Count As %
Medicine and Dentistry 8 30%
Biochemistry, Genetics and Molecular Biology 5 19%
Pharmacology, Toxicology and Pharmaceutical Science 2 7%
Immunology and Microbiology 2 7%
Agricultural and Biological Sciences 1 4%
Other 2 7%
Unknown 7 26%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 January 2018.
All research outputs
#9,481,868
of 12,381,422 outputs
Outputs from BMC Cancer
#2,680
of 4,524 outputs
Outputs of similar age
#230,622
of 352,327 outputs
Outputs of similar age from BMC Cancer
#168
of 309 outputs
Altmetric has tracked 12,381,422 research outputs across all sources so far. This one is in the 20th percentile – i.e., 20% of other outputs scored the same or lower than it.
So far Altmetric has tracked 4,524 research outputs from this source. They receive a mean Attention Score of 3.9. This one is in the 33rd percentile – i.e., 33% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 352,327 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 28th percentile – i.e., 28% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 309 others from the same source and published within six weeks on either side of this one. This one is in the 39th percentile – i.e., 39% of its contemporaries scored the same or lower than it.